According to Arunish Chawla, secretary of the Department of Pharmaceuticals, India plans to incentivise local production of GLP-1 drugs, which treat diabetes and obesity, starting in 2026. GLP-1 drugs, initially approved for diabetes, are now widely used for obesity treatment due to their ability to slow digestion and promote a feeling of fullness. Danish pharmaceutical company Novo Nordisk’s patent on…